Myeloma Combination Cuts Line for FDA Approval After Strong ASH Results

Pharmalittle: We're reading about obesity drug lawsuits, Ramaswamy's latest startup, and much more

The FDA gave a Commissioner's National Priority Voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma

FDA ‘proactively’ hands J&J a voucher; Pfizer issues 2026 forecasts

The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new cell therapy player emerged and Sanofi cut deals with two startups.

J&J claims FDA's latest national priority voucher

The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma

Myeloma Combination Cuts Line for FDA Approval After Strong ASH Results

(MedPage Today) -- Under a program designed to accelerate the approval of products that could address key national priorities, the FDA said it proactively awarded a national priority voucher to teclistamab (Tecvayli) in combination with daratumumab...

Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA grants a priority voucher for Tec-Dara, showcasing significant survival benefits in relapsed/refractory multiple myeloma, enhancing treatment options.

FDA Awards National Priority Voucher to Teclistamab Plus Daratumumab in Relapsed/Refractory Multiple Myeloma

FDA grants a national priority voucher to teclistamab and daratumumab for relapsed/refractory multiple myeloma, enhancing treatment approval speed.